3. Poniard Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of cancer therapeutics. The company's lead product candidate is Picoplatin, an intravenous platinum-based chemotherapeutic designed to treat solid tumors that are resistant to existing platinum-based cancer therapies.
Analysts polled by Bloomberg expect loss per share of 69 cents for 2010, down from $1.31 per share reported during 2009. For 2011, loss per share is likely to contract to 41 cents, analysts foresee.
The company recently announced the receipt of Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to conduct two Phase III clinical studies of Picoplatin, its lead product candidate in the treatment of second-line small cell lung cancer (SCLC) and second-line ovarian cancer in China.Of the two analysts covering the stock, 50% recommend a buy, while the remaining rate a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 186% to $1 in value from current levels.